<DOC>
	<DOC>NCT00924573</DOC>
	<brief_summary>Primary objective of this study is to confirm the efficacy of HOE490 O (glimepiride/metformin) compared with placebo on top of glimepiride in HbA1c change. Secondary objectives of this study is to evaluate the safety of HOE490 O (glimepiride/metformin) compared with placebo on top of glimepiride as well as other efficacy parameters</brief_summary>
	<brief_title>Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride</brief_title>
	<detailed_description>Patients treated with 2-6mg/day of glimepiride will be recruited. The study period consists of screening phase of 6 weeks and double-blinded phase of 24 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes Mellitus patients treated with constant dose of glimepiride on top of diet and exercise Patients who gave informed consent to participate in the study Patients with HbA1c of &lt; 7.0 % and &gt; 11.0 % Patients with any following laboratory test abnormality : ALT and/or AST: &gt; 3 X ULN Neutrophils: &lt; 1,000/mm3 and/or platelets &lt; 100,000/mm3 Hemoglobin: &lt;11 g/dL Creatinine: &gt;= 1.3 mg/dL in case of male or &gt;= 1.0 mg/dL in case of female The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Glimepiride</keyword>
	<keyword>Metformin</keyword>
	<keyword>Combination Drug Therapy</keyword>
</DOC>